- Home
- ACR vs BDTX Comparison
ACR vs BDTX Comparison
Compare ACR & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACR
- BDTX
- Stock Information
- Founded
- ACR 2005
- BDTX 2014
- Country
- ACR United States
- BDTX United States
- Employees
- ACR N/A
- BDTX N/A
- Industry
- ACR Real Estate Investment Trusts
- BDTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ACR Real Estate
- BDTX Health Care
- Exchange
- ACR Nasdaq
- BDTX Nasdaq
- Market Cap
- ACR 154.8M
- BDTX 181.4M
- IPO Year
- ACR N/A
- BDTX 2020
- Fundamental
- Price
- ACR $20.37
- BDTX $4.18
- Analyst Decision
- ACR Buy
- BDTX Strong Buy
- Analyst Count
- ACR 2
- BDTX 5
- Target Price
- ACR $23.50
- BDTX $10.40
- AVG Volume (30 Days)
- ACR 19.2K
- BDTX 1.1M
- Earning Date
- ACR 10-29-2025
- BDTX 11-04-2025
- Dividend Yield
- ACR N/A
- BDTX N/A
- EPS Growth
- ACR N/A
- BDTX N/A
- EPS
- ACR 0.04
- BDTX 0.25
- Revenue
- ACR $86,599,000.00
- BDTX $70,000,000.00
- Revenue This Year
- ACR $7.03
- BDTX N/A
- Revenue Next Year
- ACR $3.26
- BDTX N/A
- P/E Ratio
- ACR $488.32
- BDTX $16.70
- Revenue Growth
- ACR 12.74
- BDTX N/A
- 52 Week Low
- ACR $14.87
- BDTX $1.20
- 52 Week High
- ACR $23.81
- BDTX $4.43
- Technical
- Relative Strength Index (RSI)
- ACR 43.27
- BDTX 64.11
- Support Level
- ACR $20.21
- BDTX $3.69
- Resistance Level
- ACR $20.96
- BDTX $4.38
- Average True Range (ATR)
- ACR 0.43
- BDTX 0.26
- MACD
- ACR -0.06
- BDTX 0.01
- Stochastic Oscillator
- ACR 14.16
- BDTX 74.76
About ACR ACRES Commercial Realty Corp.
ACRES Commercial Realty Corp is a commercial real estate investment trust that focuses on originating, holding and managing commercial real estate (CRE) mortgage loans and equity investments in commercial real estate properties through direct ownership and joint ventures. The company invests in commercial real-estate-related assets, including whole loans, A notes, B notes, mezzanine loans, and mortgage-related securities, as well as commercial finance assets, which include other asset-backed securities, senior secured corporate loans, equipment leases and notes, trust preferred securities, debt tranches of collateralize debt obligations, and private equity investments mainly issued by financial institutions.
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.